↓ Skip to main content
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news
1 news outlet
patent
2 patents
guideline
1 clinical guideline source

Readers on

mendeley
101 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma
Published in
Cancer (0008543X), November 2010
DOI 10.1002/cncr.25515
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Netherlands 1 <1%
Unknown 100 99%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Ph. D. Student 16 16%
Other 12 12%
Researcher 12 12%
Student > Master 11 11%
Student > Bachelor 10 10%
Other 18 18%
Unknown 22 22%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 37 37%
Agricultural and Biological Sciences 13 13%
Biochemistry, Genetics and Molecular Biology 11 11%
Nursing and Health Professions 4 4%
Neuroscience 2 2%
Other 4 4%
Unknown 30 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 February 2021.
All research outputs
#3,532,270
of 34,559,526 outputs
Outputs from Cancer (0008543X)
#3,209
of 19,200 outputs
Outputs of similar age
#19,383
of 255,304 outputs
Outputs of similar age from Cancer (0008543X)
#24
of 160 outputs
Altmetric has tracked 34,559,526 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 19,200 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.0. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 255,304 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 160 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.